Accuray Incorporated (NASDAQ:ARAY – Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 3,600,000 shares, a decline of 8.6% from the October 31st total of 3,940,000 shares. Based on an average daily volume of 633,300 shares, the days-to-cover ratio is currently 5.7 days.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC acquired a new stake in shares of Accuray in the second quarter valued at approximately $910,000. Foundry Partners LLC increased its position in Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after acquiring an additional 741,900 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Accuray by 9.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock valued at $181,000 after acquiring an additional 6,583 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after acquiring an additional 230,695 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in shares of Accuray in the second quarter worth $132,000. 64.08% of the stock is owned by institutional investors and hedge funds.
Accuray Stock Down 3.6 %
NASDAQ:ARAY opened at $2.15 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The stock has a 50 day moving average of $1.86 and a 200-day moving average of $1.85. The firm has a market capitalization of $216.23 million, a PE ratio of -12.65 and a beta of 1.40. Accuray has a 52 week low of $1.40 and a 52 week high of $3.05.
Wall Street Analyst Weigh In
Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.
Check Out Our Latest Stock Report on ARAY
Accuray Company Profile
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Featured Articles
- Five stocks we like better than Accuray
- Which Wall Street Analysts are the Most Accurate?
- How to Master Trading Discipline: Overcome Emotional Challenges
- The Most Important Warren Buffett Stock for Investors: His Own
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- How to Start Investing in Real Estate
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.